OBT: Oxford BioTherapeutics inks multiyear collaboration with Roche to discover novel targets for antibodybased therapeutics to treat cancer
Oxford BioTherapeutics (OBT), a clinical stage oncology company with a pipeline of immuno─oncology (IO) and antibody drug conjugate (ADC)─based therapies, announced a multi─year collaboration with Roche to
Read full article »
OBT is a biotechnology company that focuses on the discovery and development of therapeutics for the treatment of cancer.
Read more